AOP Orphan, Cardiome deal

Cardiome granted AOP Orphan rights to market Aggrastat tirofiban in Austria, Hungary, Switzerland and other Eastern European territories. The non-peptide integrin alpha(2b)beta(3) ( GPIIb/IIIa; CD41/CD61) antagonist is approved in the U.S. and EU to treat acute coronary syndrome (ACS). The partners said financial terms are not disclosed. ...